Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP)

$5.68 -0.07 (-1.26%)
Market Cap N/A
Revenue (ttm) 84.51M
Net Income (ttm) -60.64M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 304
Avg Vol 18,892
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 79%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 652 4500
Address:
1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States
Zellchair
Zellchair Jul. 18 at 5:47 PM
$FBIO $FBIOP I felt I should send out a short comment on the phone given that I have written so much about the case and not everyone who reads on substack reads here on stocktwits. https://zellchair.substack.com/p/fortress-biotech-sold-shares-in-fbiop
0 · Reply
Kconn52
Kconn52 Jul. 18 at 5:42 PM
$FBIOP I think I probably bought the shares you sold. 😁
0 · Reply
Zellchair
Zellchair Jul. 17 at 6:14 PM
$FBIO $FBIOP Perfect trading range. Those who want to reduce or increase their risk can do so without further volatility. I have sold more FBIOP today, and bought a little more $DERM.
0 · Reply
OldManLogan
OldManLogan Jul. 17 at 1:04 PM
$FBIO $FBIOP Stock is so undervalued even based on DERM ownership alone, that about ZERO value was assigned to CAEL... this is also the advantage of the FBIO model with such a diversity of compounds being developed by partner companies...
1 · Reply
Zellchair
Zellchair Jul. 17 at 12:30 PM
$FBIO $FBIOP I find it strange that when there is undoubtedly negative news, most of the positive comments appear at the same time… Why not be transparent and call it what it is?
2 · Reply
Kconn52
Kconn52 Jul. 17 at 12:15 PM
$FBIOP mildly disappointing news but so much more positive going on with this company. As long as $FBIO is trading above $1 this is money good and the accumulated dividend clicks along at $.19 per share per month.
0 · Reply
Zellchair
Zellchair Jul. 16 at 9:35 PM
$FBIO $FBIOP 8-K from CFO now. Same info as AstraZeneca/Alexion.
2 · Reply
Zellchair
Zellchair Jul. 16 at 9:02 PM
$FBIO $FBIOP If I hadn't gone on a trip this morning (Swedish time), I would have written an updated view on Substack. I won't do it on my phone, so if there is an update, it will be at least 7-10 days away. Today's news was of course very disappointing and, for me/my opinion, also unexpected. At least as disappointing and worse that there has been no communication from Fortress. If there is no PR before opening tomorrow, I plan to sell more. I think you have to accept today's reaction that FBIOP will take more of a beating, considering how the CAEL-101 deal was structured with $19.6M directly to Fortress upon FDA approval, while FBIO is doing better when $DERM went up a bit. Unfortunately (for me), I think that trend will continue due to lower volume in FBIOP. Given that Fortress does not receive any milestones, royalties or annual dividends from DERM and Dotinurad and Triplex are years away, almost everything depends on CUTX-101 for reinvested dividends in the near term now.
3 · Reply
Zellchair
Zellchair Jul. 16 at 6:09 PM
$FBIO $FBIOP If there had been contrary news, that CAEL-101 had reached its primary goal in the study, do you really think Fortress would NOT have realesed that positive news 12 hours later?
2 · Reply
Zellchair
Zellchair Jul. 16 at 4:54 PM
$FBIO $FBIOP Obviously bad news for Fortress and very bad management by the company not to come out with this information themselves before market open, 7,5 hours after AstraZeneca/Alexion… Sold a lot today.
1 · Reply
Latest News on FBIOP
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

May 30, 2025, 10:47 AM EDT - 7 weeks ago

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

FBIO

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 15, 2025, 4:05 PM EDT - 2 months ago

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

FBIO

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 7, 2025, 8:00 AM EDT - 2 months ago

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

FBIO

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 7:39 PM EDT - 4 months ago

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

FBIO

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

Mar 17, 2025, 8:55 AM EDT - 4 months ago

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

FBIO

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Jan 27, 2025, 8:30 AM EST - 6 months ago

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

FBIO

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Jan 6, 2025, 8:00 AM EST - 6 months ago

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

FBIO

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Nov 14, 2024, 4:10 PM EST - 8 months ago

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

Fortress Biotech to Participate in October 2024 Investor Conferences

Sep 26, 2024, 8:30 AM EDT - 10 months ago

Fortress Biotech to Participate in October 2024 Investor Conferences

FBIO

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

Sep 20, 2024, 8:30 AM EDT - 10 months ago

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

FBIO

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:30 AM EDT - 11 months ago

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FBIO

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

Jul 25, 2024, 8:30 AM EDT - 1 year ago

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

FBIO

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Jul 5, 2024, 4:05 PM EDT - 1 year ago

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

FBIO

Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 10:42 PM EST - 2 years ago

Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript

FBIO

Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript

Aug 9, 2022, 9:05 PM EDT - 3 years ago

Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript

FBIO

Plenty Of Further Upside In Fortress Biotech

Mar 19, 2019, 12:01 PM EDT - 6 years ago

Plenty Of Further Upside In Fortress Biotech

FBIO

Zellchair
Zellchair Jul. 18 at 5:47 PM
$FBIO $FBIOP I felt I should send out a short comment on the phone given that I have written so much about the case and not everyone who reads on substack reads here on stocktwits. https://zellchair.substack.com/p/fortress-biotech-sold-shares-in-fbiop
0 · Reply
Kconn52
Kconn52 Jul. 18 at 5:42 PM
$FBIOP I think I probably bought the shares you sold. 😁
0 · Reply
Zellchair
Zellchair Jul. 17 at 6:14 PM
$FBIO $FBIOP Perfect trading range. Those who want to reduce or increase their risk can do so without further volatility. I have sold more FBIOP today, and bought a little more $DERM.
0 · Reply
OldManLogan
OldManLogan Jul. 17 at 1:04 PM
$FBIO $FBIOP Stock is so undervalued even based on DERM ownership alone, that about ZERO value was assigned to CAEL... this is also the advantage of the FBIO model with such a diversity of compounds being developed by partner companies...
1 · Reply
Zellchair
Zellchair Jul. 17 at 12:30 PM
$FBIO $FBIOP I find it strange that when there is undoubtedly negative news, most of the positive comments appear at the same time… Why not be transparent and call it what it is?
2 · Reply
Kconn52
Kconn52 Jul. 17 at 12:15 PM
$FBIOP mildly disappointing news but so much more positive going on with this company. As long as $FBIO is trading above $1 this is money good and the accumulated dividend clicks along at $.19 per share per month.
0 · Reply
Zellchair
Zellchair Jul. 16 at 9:35 PM
$FBIO $FBIOP 8-K from CFO now. Same info as AstraZeneca/Alexion.
2 · Reply
Zellchair
Zellchair Jul. 16 at 9:02 PM
$FBIO $FBIOP If I hadn't gone on a trip this morning (Swedish time), I would have written an updated view on Substack. I won't do it on my phone, so if there is an update, it will be at least 7-10 days away. Today's news was of course very disappointing and, for me/my opinion, also unexpected. At least as disappointing and worse that there has been no communication from Fortress. If there is no PR before opening tomorrow, I plan to sell more. I think you have to accept today's reaction that FBIOP will take more of a beating, considering how the CAEL-101 deal was structured with $19.6M directly to Fortress upon FDA approval, while FBIO is doing better when $DERM went up a bit. Unfortunately (for me), I think that trend will continue due to lower volume in FBIOP. Given that Fortress does not receive any milestones, royalties or annual dividends from DERM and Dotinurad and Triplex are years away, almost everything depends on CUTX-101 for reinvested dividends in the near term now.
3 · Reply
Zellchair
Zellchair Jul. 16 at 6:09 PM
$FBIO $FBIOP If there had been contrary news, that CAEL-101 had reached its primary goal in the study, do you really think Fortress would NOT have realesed that positive news 12 hours later?
2 · Reply
Zellchair
Zellchair Jul. 16 at 4:54 PM
$FBIO $FBIOP Obviously bad news for Fortress and very bad management by the company not to come out with this information themselves before market open, 7,5 hours after AstraZeneca/Alexion… Sold a lot today.
1 · Reply
Zellchair
Zellchair Jul. 16 at 4:33 PM
$FBIO $FBIOP …
1 · Reply
Zellchair
Zellchair Jul. 16 at 4:24 PM
$FBIO $FBIOP For over 10 hours, everyone following AstraZeneca/Alexion has been sitting on the news that CAEL-101 did not meet its primary end point in P3a-b. But you are sitting there unknowingly buying thousands of my shares when I significantly reduce my risk… And don't come and say I didn't warn you...
0 · Reply
TimmyH67
TimmyH67 Jul. 16 at 12:01 AM
$FBIOP funny how the New Investor Presentation makes no mention of the fact that they can’t or won’t pay their debts to their “preferred “ shareholders. Just a real time example of how they are deceiving investors. Lindsey and Company showing how crooked they really are.
3 · Reply
HumbleLearner69
HumbleLearner69 Jul. 15 at 11:23 PM
$FBIO $FBIOP $DERM
0 · Reply
Zellchair
Zellchair Jul. 15 at 6:58 PM
$FBIO $FBIOP Already stacked high. https://cj.sina.com.cn/articles/view/5182171545/134e1a999020025u3i?froms=ggmp
0 · Reply
FinSUN
FinSUN Jul. 14 at 2:43 PM
$FBIO $FBIOP manipulation !
1 · Reply
Zellchair
Zellchair Jul. 14 at 1:59 PM
$FBIO $FBIOP $DERM New Investor Presentation released today for July for both Fortress and Journey: https://www.fortressbiotech.com/news-media/presentations
1 · Reply
Sawnchey
Sawnchey Jul. 14 at 1:49 PM
$FBIO $FBIOP Just to give a snapshot of how broken the valuation for FBIO is, the stock should rise about 1 cent for every 4 cents that DERM goes up. This is because when you factor in both common and preferreds, each FBIO share owns about 0.25 DERM shares. At the time I began typing DERM is up 70 cents and FBIO is down 2. I appreciate the complexities of Fortress's position with regards to debt, dividends, cash runway etc But this is like owning shares in an unhedged oil company and watching it fail to rise while the price of oil spikes! Make no mistake, eventually someone smart with a lot of cash is going to recognise this arbitrage opportunity. Also for those interested, I am about 6:1 preferreds to commons.
1 · Reply
Zschopower
Zschopower Jul. 14 at 1:20 PM
$FBIOP 💎💎💎 👉🏼
0 · Reply
Zellchair
Zellchair Jul. 14 at 10:43 AM
$FBIO $FBIOP Following approval in December and a soft launch, Dotinurad is being launched broadly starting today in China. The need within Gout alone is extensive to say the least and appears to be increasing: "The prevalence of gout is increasing, and it is estimated that there are currently about 23 million patients with gout in China. It is expected that the number of patients will further increase in the near future due to changes in lifestyle and dietary preferences in accordance with socioeconomic development." https://www.eisai.com/news/2025/news202546.html
2 · Reply
makrodimutross
makrodimutross Jul. 13 at 11:24 PM
$FBIO $FBIOP My opinion is that, if all assets become unlocked under the Fortress name over the next 5 years, this company will be valued conservatively at a 5 b minimum market cap. It's also my opinion that the company cannot reach this valuation until all debt is considered good debt, and the company can continue as a going concern without any further private placements, sweetheart deals, or any other dilutive financing. DERM should already be at the self-financing stage now. I am personally very excited to see Triplex hit the market during this timeframe. Dotinurad is essentially de-risked, and Crystalys with the help of Novo Nordisk will find a way to bring this to the ex-Japan ex-China markets promptly.
0 · Reply
Zellchair
Zellchair Jul. 13 at 6:23 PM
$FBIO $FBIOP And with volume and close to 97% in FBIOP and the dividend it can give every month, it of course helps as a start of the transaction for more FBIO by reinvesting the FBIOP dividend into FBIO, if/when I believe the risk-reward is better there as a step two. For step one, I hope and believe it will be to reinvest the first large accumulated dividend from FBIOP, into more FBIOP, as I hope and believe that FBIOP will have then come down somewhat just after the initial rush into the first X-day.
0 · Reply